DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dianthus Therapeutics, Inc. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$74.54+2.45 (+3.40%)
Close on Oct 19, 2026
- Market cap
- $4.18B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
66M of 56M shares
Institutional holders
269
63 new, 32 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 66 sales
Net sold $71.20M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 6,632,303 | 12.10% | 13G (passive) amendment | Jul 31, 2026 |
| Abigail P. Johnson | 5,970,638 | 15.00% | 13G (passive) amendment | Sep 30, 2025 |
| Tomas Kiselak | 4,052,052 | 9.90% | 13D (active) amendment | Sep 11, 2025 |
| BlackRock, Inc. | 3,504,166 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Avidity Partners Management LP | 3,378,939 | 9.90% | 13D (active) amendment | Mar 17, 2025 |
| Wellington Management Group LLP | 3,229,882 | 5.90% | 13G (passive) | Jun 30, 2026 |
| RA Capital Healthcare Fund, L.P. | 2,866,733 | 8.90% | 13G (passive) amendment | Mar 31, 2025 |
| Rajeev Shah | 2,866,733 | 9.40% | 13G (passive) amendment | Dec 31, 2024 |
| Sirenia Capital Management LP | 2,798,122 | 5.30% | 13G (passive) | Mar 31, 2026 |
| RA Capital Management, L.P. | 2,611,733 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Management Company LLP | 2,577,662 | 6.30% | 13G (passive) | Sep 30, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. | 2,357,702 | 7.34% | 13G (passive) | Mar 17, 2025 |
| Point72 Asset Management, L.P. | 2,121,140 | 5.30% | 13G (passive) | Sep 11, 2025 |
| Ting Jia | 2,110,167 | 7.10% | 13G (passive) amendment | Dec 31, 2024 |
| Steven A. Cohen | 1,894,304 | 5.90% | 13G (passive) | Apr 10, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DNTH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 8,199,893 | 14.66% | $799.33M | +432,207 | 0.03% |
| BlackRock, Inc. | 4,123,822 | 7.37% | $401.99M | +948,119 | 0.01% |
| T. Rowe Price Investment Management, Inc. | 3,888,456 | 6.95% | $379.05K | +2,596,274 | 0.25% |
| Wellington Management Group Llp | 3,229,882 | 5.77% | $314.85M | +634,099 | 0.05% |
| Fairmount Funds Management LLC | 2,537,191 | 4.54% | $247.33M | – | 16.35% |
| Price T Rowe Associates Inc /Md/ | 2,514,946 | 4.50% | $245.16K | +1,367,998 | 0.02% |
| State Street Corp | 2,357,440 | 4.21% | $229.80M | +958,527 | 0.01% |
| Vanguard Capital Management LLC | 2,159,568 | 3.86% | $210.51M | +128,319 | 0.00% |
| Avidity Partners Management LP | 2,104,184 | 3.76% | $205.12M | −2,104,184 | 32.85% |
| Octagon Capital Advisors LP | 1,841,667 | 3.29% | $179.53M | −105,000 | 16.14% |
| TCG Crossover Management, LLC | 1,676,624 | 3.00% | $163.44M | – | 3.93% |
| Fred Alger Management, LLC | 1,302,493 | 2.33% | $126.97M | +140,570 | 0.42% |
| Geode Capital Management, LLC | 1,258,502 | 2.25% | $122.70M | +342,291 | 0.01% |
| VR Adviser, LLC | 1,180,000 | 2.11% | $115.03M | – | 3.49% |
| UBS Group AG | 1,140,260 | 2.04% | $111.15M | +358,978 | 0.01% |
| Deerfield Management Company, L.P. (Series C) | 1,125,313 | 2.01% | $109.70M | +105,500 | 1.14% |
| Jennison Associates LLC | 1,021,763 | 1.83% | $99.60M | +536,627 | 0.06% |
| Polar Capital Holdings Plc | 1,018,726 | 1.82% | $99.31M | −57,283 | 0.23% |
| Citadel Advisors LLC | 974,911 | 1.74% | $95.03M | −635,572 | 0.01% |
| Franklin Resources Inc | 968,983 | 1.73% | $94.46M | +801 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 269 | 66M | 100.0% | 63 / 117 | 69 / 32 | 14M | 12M |
| Q1 2026 | 241 | 64M | 100.0% | 97 / 84 | 54 / 20 | 24M | 7M |
| Q4 2025 | 166 | 49M | 87.8% | 47 / 76 | 26 / 18 | 11M | 9M |
| Q3 2025 | 140 | 47M | 83.8% | 51 / 43 | 34 / 13 | 16M | 8M |
| Q2 2025 | 102 | 39M | 69.9% | 18 / 30 | 39 / 14 | 5M | 3M |
| Q1 2025 | 98 | 38M | 67.4% | 16 / 29 | 31 / 12 | 7M | 4M |
| Q4 2024 | 95 | 35M | 62.8% | 16 / 40 | 25 / 12 | 6M | 2M |
| Q3 2024 | 91 | 31M | 56.1% | 25 / 31 | 20 / 6 | 5M | 2M |
| Q2 2024 | 74 | 30M | 53.1% | 28 / 18 | 17 / 30 | 6M | 2M |
| Q1 2024 | 76 | 26M | 46.7% | 39 / 24 | 8 / 2 | 17M | 1M |
| Q4 2023 | 39 | 11M | 19.0% | 10 / 12 | 6 / 1 | 1M | 0M |
| Q3 2023 | 30 | 10M | 18.0% | 30 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DNTH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,649,920 | 2.95% | $160.83M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,594,117 | 2.85% | $148.27M | 0.15% | May 31, 2026 |
| Vanguard Health Care Fund | 1,503,955 | 2.69% | $160.80M | 0.42% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,302,913 | 2.33% | $127.01M | 1.18% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,214,601 | 2.17% | $118.40M | 0.14% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1,155,511 | 2.07% | $112.64M | 1.21% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 730,062 | 1.31% | $78.06M | 3.55% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 673,057 | 1.20% | $65.61M | 0.45% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 624,586 | 1.12% | $60.88M | 1.21% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 517,343 | 0.92% | $55.31M | 0.16% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 514,500 | 0.92% | $50.15M | 0.22% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 468,387 | 0.84% | $50.08M | 0.57% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 457,638 | 0.82% | $44.61M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 453,246 | 0.81% | $44.18M | 0.45% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 444,440 | 0.79% | $43.32M | 0.28% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marino Garcia | CEO AND PRESIDENT, Director | 65,292 | 0.12% | Aug 7, 2026 |
| Edward Carr | CHIEF ACCOUNTING OFFICER | 700 | 0.00% | Sep 18, 2026 |
| Simrat Randhawa | EVP, Head of R&D | 4,000 | 0.01% | Sep 3, 2026 |
| Adam M. Veness | SVP, General Counsel and Sec. | 15,000 | 0.03% | Aug 14, 2026 |
| Ryan Savitz | EVP, CFO & CBO | 5,566 | 0.01% | Jul 13, 2026 |
| Simon Read | Director | 0 | – | Aug 19, 2026 |
| Anne McGeorge | Director | 1,250 | 0.00% | Aug 11, 2026 |
| Steven J. Romano | Director | – | – | May 22, 2026 |
| Jonathan Violin | Director | – | – | May 22, 2026 |
| Alison Frances Lawton | Director | – | – | May 22, 2026 |
| Paula Soteropoulos | Director | 0 | – | May 22, 2026 |
| Sujay Kango | Director | – | – | May 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −1,100 | $103.20 | $113.52K | 700 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −700 | $104.39 | $73.07K | 0 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −3,501 | $102.39 | $358.47K | 1,800 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −6,771 | $101.37 | $686.38K | 5,301 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −7,928 | $100.43 | $796.21K | 12,072 |
| Edward Carr CHIEF ACCOUNTING OFFICER | Sep 17, 2026 | Option exercise | +20,000 | $17.88 | $357.60K | 20,000 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −13,309 | $106.74 | $1.42M | 4,000 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −7,215 | $106.25 | $766.59K | 17,309 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −2,600 | $105.19 | $273.49K | 24,524 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Option exercise | +9,375 | $22.07 | $206.91K | 27,124 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Option exercise | +6,249 | $21.77 | $136.04K | 17,749 |
| Simrat Randhawa EVP, Head of R&D | Sep 1, 2026 | Option exercise | +7,500 | $17.88 | $134.10K | 11,500 |
| Simon Read Director | Aug 19, 2026 | Sale(10b5-1 plan) | −2,778 | $117.55 | $326.55K | 0 |
| Simon Read Director | Aug 19, 2026 | Option exercise | +2,778 | $18.36 | $51.00K | 2,778 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 13, 2026 | Option exercise | +15,000 | $18.17 | $272.55K | 15,000 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −470 | $111.05 | $52.19K | 397 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −397 | $111.77 | $44.37K | 0 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −272 | $109.96 | $29.91K | 867 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −831 | $108.95 | $90.54K | 1,139 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −737 | $108.17 | $79.72K | 1,970 |
| Simon Read Director | Aug 10, 2026 | Sale(10b5-1 plan) | −70 | $107.11 | $7.50K | 2,707 |
| Simon Read Director | Aug 10, 2026 | Option exercise | +2,777 | $18.36 | $50.99K | 2,777 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 10, 2026 | Sale(10b5-1 plan) | −16,167 | $110.38 | $1.78M | 0 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 10, 2026 | Option exercise | +16,167 | $17.88 | $289.07K | 16,167 |
| Anne McGeorge Director | Aug 10, 2026 | Option exercise | +1,250 | $19.36 | $24.20K | 1,250 |
| Anne McGeorge Director | Aug 10, 2026 | Option exercise | +6,500 | $11.20 | $72.80K | 7,750 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −1,450 | $107.58 | $155.99K | 6,300 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −2,800 | $108.38 | $303.46K | 3,500 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −1,800 | $109.30 | $196.74K | 1,700 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −700 | $111.41 | $77.99K | 0 |
| Anne McGeorge Director | Aug 10, 2026 | Sale(10b5-1 plan) | −1,000 | $110.64 | $110.64K | 700 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 7, 2026 | Option exercise | +3,833 | $17.88 | $68.53K | 3,833 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 7, 2026 | Sale(10b5-1 plan) | −3,217 | $110.61 | $355.83K | 616 |
| Adam M. Veness SVP, General Counsel and Sec. | Aug 7, 2026 | Sale(10b5-1 plan) | −616 | $111.18 | $68.49K | 0 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −21,909 | $108.72 | $2.38M | 65,292 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −10,384 | $107.49 | $1.12M | 220,908 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Option exercise | +126,000 | $8.44 | $1.06M | 231,292 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Option exercise | +40,000 | $8.44 | $337.60K | 105,292 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −23,907 | $108.05 | $2.58M | 197,001 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −104,091 | $107.96 | $11.24M | 87,102 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −800 | $110.76 | $88.61K | 191,292 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −2,536 | $110.02 | $279.01K | 192,092 |
| Marino Garcia CEO AND PRESIDENT, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −2,373 | $109.10 | $258.89K | 194,628 |
| Ryan Savitz EVP, CFO & CBO | Jul 9, 2026 | Sale(10b5-1 plan) | −15,329 | $101.24 | $1.55M | 5,566 |
| Ryan Savitz EVP, CFO & CBO | Jul 9, 2026 | Sale(10b5-1 plan) | −5,566 | $101.97 | $567.57K | 0 |
| Ryan Savitz EVP, CFO & CBO | Jul 9, 2026 | Sale(10b5-1 plan) | −10,354 | $100.22 | $1.04M | 20,895 |
| Ryan Savitz EVP, CFO & CBO | Jul 9, 2026 | Option exercise | +31,249 | $21.77 | $680.29K | 31,249 |
| Adam M. Veness SVP, General Counsel and Sec. | Jun 17, 2026 | Sale(10b5-1 plan) | −16,771 | $80.34 | $1.35M | 13,229 |
| Adam M. Veness SVP, General Counsel and Sec. | Jun 17, 2026 | Option exercise | +30,000 | $17.88 | $536.40K | 30,000 |
| Adam M. Veness SVP, General Counsel and Sec. | Jun 17, 2026 | Sale(10b5-1 plan) | −13,229 | $81.38 | $1.08M | 0 |
| Simrat Randhawa EVP, Head of R&D | Jun 1, 2026 | Option exercise | +3,998 | $8.44 | $33.74K | 7,998 |
| Simrat Randhawa EVP, Head of R&D | Jun 1, 2026 | Option exercise | +6,908 | $17.88 | $123.52K | 14,906 |
| Simrat Randhawa EVP, Head of R&D | Jun 1, 2026 | Option exercise | +6,249 | $21.77 | $136.04K | 21,155 |
| Simrat Randhawa EVP, Head of R&D | Jun 1, 2026 | Option exercise | +9,375 | $22.07 | $206.91K | 30,530 |
| Simrat Randhawa EVP, Head of R&D | Jun 1, 2026 | Sale(10b5-1 plan) | −5,428 | $89.72 | $487.00K | 25,102 |
| Simrat Randhawa EVP, Head of R&D | Jun 1, 2026 | Sale(10b5-1 plan) | −4,159 | $91.37 | $380.01K | 4,000 |
| Simrat Randhawa EVP, Head of R&D | Jun 1, 2026 | Sale(10b5-1 plan) | −16,943 | $90.72 | $1.54M | 8,159 |
| Paula Soteropoulos Director | May 8, 2026 | Sale(10b5-1 plan) | −599 | $85.47 | $51.20K | 0 |
| Paula Soteropoulos Director | May 8, 2026 | Option exercise | +599 | $8.44 | $5.06K | 599 |
| Ryan Savitz EVP, CFO & CBO | Apr 9, 2026 | Sale(10b5-1 plan) | −8,224 | $89.84 | $738.84K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Carr Edward Officer | Sep 17, 2026 | 20,000 | $2.05M | Sep 17, 2026 | Exercise of Stock Options |
| Randhawa Simrat Officer | Sep 1, 2026 | 23,124 | $2.44M | Sep 1, 2026 | Exercise of Stock Options |
| Veness Adam Officer | Aug 10, 2026 | 16,167 | $1.76M | Aug 10, 2026 | Exercise of Stock Options |
| Simon Read Officer | Aug 10, 2026 | 5,550 | $624.38K | Aug 10, 2026 | Stock Option Exercise |
| M. McGeorge Anne Director | Aug 10, 2026 | 7,750 | $844.13K | Aug 10, 2026 | Exercise of Stock Options |
| Garcia Marino Officer | Aug 7, 2026 | 126,000 | $13.62M | Aug 7, 2026 | Exercise of Options Under a Registered Plan |
| Veness Adam Officer | Aug 7, 2026 | 3,833 | $421.32K | Aug 7, 2026 | Exercise of Stock Options |
| Garcia Marino Director, Officer | Aug 7, 2026 | 40,000 | $4.40M | Aug 7, 2026 | Exercise of Stock Options |
| Savitz Ryan Officer | Jul 9, 2026 | 31,249 | $3.06M | Jul 9, 2026 | Exercise of Stock Options |
| M. Veness Adam Officer | Jun 17, 2026 | 30,000 | $2.37M | Jun 17, 2026 | Exercise of Stock Options |
| Randhawa Simrat Officer | Jun 1, 2026 | 26,530 | $2.47M | Jun 1, 2026 | Exercise of Stock Options |
| Savitz Ryan Officer | Apr 9, 2026 | 8,224 | $719.44K | Apr 9, 2026 | Exercise of Stock Options |
| Savitz Ryan Officer | Mar 31, 2026 | 114,367 | $9.09M | Mar 31, 2026 | Exercise of Stock Options |
| C. Soteropoulos Paula Director | Mar 31, 2026 | 1,198 | $95.18K | Mar 31, 2026 | Exercise of Stock Options |
| C. Soteropoulos Paula Director | Mar 24, 2026 | 27,594 | $2.19M | Mar 24, 2026 | Exercise of Stock Options |